Page last updated: 2024-09-05

lapatinib and transforming growth factor alpha

lapatinib has been researched along with transforming growth factor alpha in 2 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (transforming growth factor alpha)	Trials (transforming growth factor alpha)	Recent Studies (post-2010) (transforming growth factor alpha)
1,919	305	1,442	4,301	44	623

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Civiello, G; Janne, PA; Johnson, BE; Mukohara, T	1
Bang, YJ; Cha, Y; Ham, HS; Han, SW; Im, SA; Im, YH; Kim, HP; Kim, TY; Lee, KS; Oh, DY; Park, IH; Park, JW; Rhee, J; Ro, J	1

Other Studies

2 other study(ies) available for lapatinib and transforming growth factor alpha

Article	Year
Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. Oncology, 2005, Volume: 68, Issue:4-6 Topics: Antibiotics, Antineoplastic; Butadienes; Cell Cycle; Chromones; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mesothelioma; Mitogen-Activated Protein Kinase 3; Morpholines; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pleural Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Sirolimus; Transforming Growth Factor alpha; Tumor Cells, Cultured	2005
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast cancer research and treatment, 2011, Volume: 125, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Logistic Models; Middle Aged; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Transforming Growth Factor alpha; Treatment Outcome; Up-Regulation	2011

Article

Year

Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.

Oncology, 2005, Volume: 68, Issue:4-6

Topics: Antibiotics, Antineoplastic; Butadienes; Cell Cycle; Chromones; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mesothelioma; Mitogen-Activated Protein Kinase 3; Morpholines; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pleural Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Sirolimus; Transforming Growth Factor alpha; Tumor Cells, Cultured

2005

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

Breast cancer research and treatment, 2011, Volume: 125, Issue:1

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Logistic Models; Middle Aged; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Transforming Growth Factor alpha; Treatment Outcome; Up-Regulation

2011